X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (72954) 72954
Newsletter (780) 780
Book Chapter (291) 291
Magazine Article (272) 272
Newspaper Article (264) 264
Book / eBook (129) 129
Dissertation (57) 57
Transcript (32) 32
Web Resource (27) 27
Publication (21) 21
Conference Proceeding (17) 17
Reference (10) 10
Government Document (7) 7
Book Review (5) 5
Streaming Video (4) 4
Report (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (64888) 64888
female (39825) 39825
male (36857) 36857
radiotherapy (34396) 34396
middle aged (33163) 33163
oncology (28764) 28764
aged (27918) 27918
adult (26084) 26084
cancer (18418) 18418
radiotherapy - adverse effects (18293) 18293
treatment outcome (14097) 14097
chemotherapy (13280) 13280
radiology, nuclear medicine & medical imaging (11948) 11948
care and treatment (11828) 11828
surgery (11785) 11785
radiotherapy dosage (11390) 11390
aged, 80 and over (10503) 10503
combined modality therapy (9962) 9962
retrospective studies (9962) 9962
radiation (9932) 9932
radiation therapy (8844) 8844
radiation-therapy (8680) 8680
follow-up studies (8650) 8650
therapy (7593) 7593
neoplasm staging (7351) 7351
adolescent (7111) 7111
medicine & public health (6603) 6603
risk factors (6478) 6478
hematology, oncology and palliative medicine (6468) 6468
prognosis (6381) 6381
time factors (6369) 6369
patients (6258) 6258
research (6209) 6209
antineoplastic combined chemotherapy protocols - therapeutic use (5963) 5963
child (5934) 5934
carcinoma (5856) 5856
irradiation (5699) 5699
survival (5506) 5506
analysis (5223) 5223
tumors (5180) 5180
health aspects (5162) 5162
radiology (5135) 5135
disease-free survival (4845) 4845
radiation injuries - etiology (4819) 4819
toxicity (4747) 4747
survival rate (4722) 4722
prospective studies (4488) 4488
antineoplastic agents - adverse effects (4386) 4386
antineoplastic combined chemotherapy protocols - adverse effects (4244) 4244
prostatic neoplasms - radiotherapy (4202) 4202
breast neoplasms - radiotherapy (4169) 4169
animals (4160) 4160
prostate cancer (3964) 3964
survival analysis (3953) 3953
quality of life (3872) 3872
metastasis (3634) 3634
risk (3607) 3607
young adult (3600) 3600
carcinoma, squamous cell - radiotherapy (3598) 3598
breast cancer (3510) 3510
management (3462) 3462
head and neck neoplasms - radiotherapy (3424) 3424
cancer therapies (3389) 3389
radiology and nuclear medicine (3377) 3377
child, preschool (3358) 3358
radiotherapy, adjuvant (3318) 3318
brachytherapy - adverse effects (3314) 3314
neoplasms - radiotherapy (3243) 3243
dose-response relationship, radiation (3226) 3226
trial (3211) 3211
neoplasms (3099) 3099
brachytherapy (3076) 3076
antineoplastic agents - therapeutic use (3075) 3075
quality-of-life (2984) 2984
medicine (2942) 2942
chemoradiotherapy (2898) 2898
head (2782) 2782
lung neoplasms - radiotherapy (2733) 2733
clinical neurology (2632) 2632
brain neoplasms - radiotherapy (2624) 2624
chemotherapy, adjuvant (2596) 2596
oncology, experimental (2565) 2565
patient outcomes (2550) 2550
clinical trials (2508) 2508
usage (2482) 2482
randomized-trial (2473) 2473
cancer patients (2464) 2464
dose fractionation (2457) 2457
cisplatin (2449) 2449
diagnosis (2445) 2445
squamous-cell carcinoma (2437) 2437
brachytherapy - methods (2432) 2432
radiation dosage (2417) 2417
recurrence (2414) 2414
nuclear radiation (2361) 2361
cisplatin - administration & dosage (2351) 2351
complications (2316) 2316
nuclear medicine (2315) 2315
breast neoplasms - surgery (2272) 2272
magnetic resonance imaging (2256) 2256
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (49) 49
Online Resources - Online (22) 22
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Scarborough Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (68113) 68113
French (1802) 1802
German (1793) 1793
Japanese (1009) 1009
Russian (864) 864
Spanish (412) 412
Chinese (352) 352
Italian (350) 350
Polish (256) 256
Dutch (121) 121
Hungarian (99) 99
Czech (92) 92
Portuguese (86) 86
Danish (60) 60
Norwegian (40) 40
Swedish (37) 37
Hebrew (32) 32
Finnish (31) 31
Romanian (20) 20
Turkish (20) 20
Croatian (18) 18
Serbian (18) 18
Bulgarian (14) 14
Slovak (12) 12
Korean (10) 10
Lithuanian (8) 8
Ukrainian (8) 8
Greek (6) 6
Icelandic (5) 5
Bosnian (2) 2
Thai (2) 2
Afrikaans (1) 1
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear. We... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 3, pp. 203 - 212
.... BEACOPP therapy was associated with higher initial rates of complete response and freedom from relapse but also with more short-term and long-term toxic effects... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 32, pp. 3651 - 3658
Purpose The Children's Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of early chemotherapy response in... 
TRIAL | MORTALITY | ABVD | POSITRON-EMISSION-TOMOGRAPHY | ONCOLOGY | INVOLVED-FIELD RADIATION | PEDIATRIC-PATIENTS | DISEASE | FOLLOW-UP | CHILDHOOD-CANCER SURVIVOR | NO RADIOTHERAPY | Cyclophosphamide - administration & dosage | Hodgkin Disease - pathology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Hodgkin Disease - radiotherapy | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Female | Child | Infant, Newborn | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Bleomycin - administration & dosage | Bleomycin - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Cisplatin - adverse effects | Vincristine - adverse effects | Doxorubicin - adverse effects | Pedi9 | ORIGINAL REPORTS | Hema14
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 332 - 339
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2014, Volume 102, Issue 3, pp. 667 - 674.e3
Objective To determine consequences of lymphoma treatments on sperm characteristics and sperm DNA, and to evaluate predictors of sperm recovery. Design... 
Internal Medicine | Obstetrics and Gynecology | sperm DNA | sperm chromatin | radiotherapy | spermatogenesis | Hodgkin | Lymphoma | chemotherapy | DNA INTEGRITY | FERTILITY PRESERVATION | CHROMATIN-STRUCTURE | TESTICULAR CANCER | CRYOPRESERVATION | SEMEN QUALITY | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | HODGKINS-DISEASE | MEN | GONADAL DYSFUNCTION | Doxorubicin - therapeutic use | Sperm Count | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | DNA - radiation effects | Mechlorethamine - therapeutic use | Case-Control Studies | Cyclophosphamide - therapeutic use | Young Adult | Bleomycin - therapeutic use | Vinblastine - adverse effects | Adult | DNA - drug effects | Spermatogenesis - radiation effects | Spermatogenesis - drug effects | Prednisone - adverse effects | Spermatozoa - radiation effects | Semen Analysis | Combined Modality Therapy | Bleomycin - adverse effects | Spermatozoa - drug effects | DNA - chemistry | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Vincristine - therapeutic use | Vincristine - adverse effects | Spermatozoa - physiology | DNA Damage | Longitudinal Studies | Doxorubicin - adverse effects | Prednisone - therapeutic use | Care and treatment | Spermatozoa | Lymphomas | Drug therapy | DNA | Cancer
Journal Article
Thyroid (New York, N.Y.), ISSN 1557-9077, 2014, Volume 24, Issue 5, pp. 918 - 922
Background: In the past decade, targeted therapy with antiangiogenic drugs has become standard of care for most types of metastatic, progressive thyroid... 
Case Studies, and Patients with Remarkable Features or Rare Disorders | PHASE-II TRIAL | TRACHEOESOPHAGEAL FISTULA | BEVACIZUMAB | ENDOCRINOLOGY & METABOLISM | SORAFENIB | CARCINOMA | RADIATION-THERAPY | Anilides - therapeutic use | Postoperative Complications - etiology | Drugs, Investigational - adverse effects | Esophageal Fistula - physiopathology | Anilides - adverse effects | Humans | Middle Aged | Drugs, Investigational - therapeutic use | Esophageal Fistula - epidemiology | Male | Protein Kinase Inhibitors - adverse effects | Respiratory Tract Fistula - etiology | Respiratory Tract Fistula - chemically induced | Pyridines - adverse effects | Phenylurea Compounds - adverse effects | Fatal Outcome | Angiogenesis Inhibitors - therapeutic use | Pyrroles - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Postoperative Complications - chemically induced | Pyridines - therapeutic use | Texas - epidemiology | Esophageal Fistula - etiology | Thyroid Neoplasms - surgery | Tracheoesophageal Fistula - epidemiology | Postoperative Complications - physiopathology | Esophageal Fistula - chemically induced | Risk Factors | Phenylurea Compounds - therapeutic use | Postoperative Complications - epidemiology | Thyroid Neoplasms - radiotherapy | Tracheoesophageal Fistula - chemically induced | Academic Medical Centers | Combined Modality Therapy - adverse effects | Thyroidectomy - adverse effects | Indoles - adverse effects | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Neck Dissection - adverse effects | Respiratory Tract Fistula - epidemiology | Indoles - therapeutic use | Tracheoesophageal Fistula - physiopathology | Quinolines - therapeutic use | Tracheoesophageal Fistula - etiology | Respiratory Tract Fistula - physiopathology | Quinolines - adverse effects | Index Medicus
Journal Article
Journal Article